My Cart

Integrin alpha 4 beta 1

Integrin alpha 4 beta 1 Overview

English NameIntegrin alpha-4/beta-1Approved Drugs3
Drugs in Clinical Trials6Target SynonymIntegrin alpha4beta1
Highest Development StageApproved
English NameIntegrin alpha-4/beta-1
Target SynonymIntegrin alpha4beta1
Approved Drugs3
Drugs in Clinical Trials6
Highest Development StageApproved

Integrin alpha 4 beta 1 Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag (1)His Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (1)Biotin-labeled (1)

Integrin alpha 4 beta 1 Background

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Integrin alpha 4 beta 1 Synonyms

Integrin alpha 4 beta 1,ITGA4&ITGB1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Natalizumab biosimilar (GENERIUM Pharmaceuticals)GNR-093Phase 3 ClinicalGenerium PharmaceuticalsMultiple Sclerosis
Details
AvicursenTV-1102; ATL/TV-1102; ATL-1102; ISIS-107248Phase 2 ClinicalIonis Pharmaceuticals IncMultiple Sclerosis; Muscular Dystrophy, Duchenne
Details
Alintegimod7HP349; 7-HP-349; 7HP-349Phase 2 Clinical7 Hills Pharma LLCCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis
Details
LLP2A alendronatePhase 1 ClinicalUniversity Of CaliforniaBone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis
Details
ABBV-243ABBV-243Phase 1 ClinicalAbbvie Inc
Details
RBx-7796RBx-7796ClinicalSun Pharmaceutical Industries LtdAsthma; Rhinitis, Allergic
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Carotegrast methylAJM-300ApprovedEa Pharma, Eisai Co LtdCarograJapanColitis, UlcerativeEa Pharma Co Ltd2022-03-28Colitis, Ulcerative
Details
Natalizumab biosimilar (Polpharma Biologics)PB-006; DST-356A1ApprovedPolpharma Biologics SaTyrukoUnited StatesMultiple Sclerosis; Crohn DiseaseSandoz Inc2023-08-24Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
Details
NatalizumabBG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-EApprovedBiogen Inc, Perrigo LlcTysabri, Antegran, AntegrenUnited StatesCrohn Disease; Multiple SclerosisBiogen Idec2004-11-23Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland